118 D. Caldeira et al. 16. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack 30. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer . Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger MT, Maas H, Voigt JU, Simoons ML, Van de Werf F. Dabigatran versus warfarin CB, Alexander JH. Apixaban in comparison with Warfarin in patients with atrial in patients with mechanical heart valves. N Engl J Med 2013;369:1206–1214. fibrillation and valvular heart disease: findings from the Apixaban for Reduction 17. Higgins JPT, Altman DG, Sterne JAC, Chapter 8: Assessing risk of bias in included in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) studies. In: JPT Higgins, S Green, eds. Cochrane Handbook for Systematic Reviews of . Trial. Circulation 2015;132:624–632. Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. 31. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, 18. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost Dabigatran versus Warfarin in patients with atrial fibrillation and valvular heart 2005;3:692–694. . disease: the RE-LY Trial. Circulation 2016;134:589–598. 19. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, 32. Dur~ aes AR, de Souza Roriz P, de Almeida Nunes B, Albuquerque FP, de Bulhoes ~ Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, FV, de Souza Fernandes AM, Aras R. Dabigatran versus Warfarin after biopros- Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron . thesis valve replacement for the management of atrial fibrillation postoperatively: Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos DAWA Pilot Study. Drugs R D 2016;16:149–154. S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, 33. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek CT, Antman EM, Braunwald E, Giugliano RP. Valvular heart disease patients on R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van . Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol 2017; Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC 69: 1372–1382. Guidelines for the management of atrial fibrillation developed in collaboration 34. Pokorney SD, Rao MP, Wojdyla DM, Gersh BJ, Lopes RD, Lewis BS, Hanna M, with EACTS. Eur Heart J 2016;37:2893–2962. . Avezum A, Wallentin L, Alexander JH. Apixaban use in patients with atrial fibril- 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: lation with bioprosthetic valves: insights from ARISTOTLE. Circulation 2015; 177–188. 132(Suppl 3):A17277–A17277. 21. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical 35. Renda G, De Caterina R, Carnicelli A, Nordio F, Mercuri M, Ruff C, Giugliano R. trials with binary outcomes. Stat Med 2002;21:1575–1600. . Outcomes in 2824 patients with valvular heart disease treated with edoxaban or 22. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K- warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2016;67:2194-2194. antagonist oral anticoagulants in patients with atrial fibrillation and previous 36. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe stroke or transient ischemic attack: a systematic review and meta-analysis of S, Breithardt G, Le HJY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation manage- randomized controlled trials. Stroke 2012;43:3298–3304. ment: a prospective survey in ESC member countries: the Euro Heart Survey on 23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med atrial fibrillation. Eur Heart J 2005;26:2422–2434. 2002;21:1539–1558. 37. Caldeira D, Ferreira JJ, Pinto FJ. The era of the novel oral anticoagulants in 24. Altman DG, Andersen PK. Calculating the number needed to treat for trials . Portugal. Rev Port Cardiol 2017;36:577–578. where the outcome is time to an event. BMJ 1999;319:1492–1495. 38. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription patterns of 25. Sterne JAC, Egger M, Moher D, Chapter 10: Addressing reporting biases. In: JPT non-vitamin K oral anticoagulants across indications and factors associated with Higgins, S Green, eds. Cochrane Handbook for Systematic Reviews of Intervention their increased prescribing in atrial fibrillation between 2012-2015: a study from Version 5.1.0: The Cochrane Collaboration; 2011. . the Norwegian Prescription Database. Drugs Aging 2017;34:635–645. 26. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insuf- 39. Loo SY, Dell’aniello S, Huiart L, Renoux C. Trends in the prescription of novel ficient information size and potentially false positive results in many meta-analy- oral anticoagulants in UK primary care. Br J Clin Pharmacol 2017;83:2096–2106. ses. J Clin Epidemiol 2008;61:763–769. 40. Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, 27. Caldeira D, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J. Thromboprophylaxis . Choudhry NK. Cost-effectiveness of oral anticoagulants for treatment of atrial with apixaban in patients undergoing major orthopedic surgery: meta- fibrillation. Circ Cardiovasc Qual Outcomes 2013;6:724–731. analysis and trial-sequential analysis. Clin Med Insights Blood Disord 2017;10: 41. Krejczy M, Harenberg J, Marx S, Obermann K, Frolich L, Wehling M. 1179545x17704660. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban 28. Rodrigues FB, Neves JB, Caldeira D, Ferro JM, Ferreira JJ, Costa J. Endovascular and apixaban in patients with non-valvular atrial fibrillation across countries. treatment versus medical care alone for ischaemic stroke: systematic review and J Thromb Thrombolysis 2014;37:507–523. meta-analysis. BMJ 2016;353:i1754. 42. Costa J, Fiorentino F, Caldeira D, Ines M, Lopes Pereira C, Pinheiro L, Vaz- 29. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, . Carneiro A, Borges M, Gouveia M. Cost-effectiveness of non-vitamin K antago- Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker nist oral anticoagulants for atrial fibrillation in Portugal. Rev Port Cardiol 2015;34: RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; Committee RAS, Investigators. 723–737. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients 43. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral with non-valvular atrial fibrillation but underlying native mitral and aortic valve anticoagulants in patients with atrial fibrillation and valvular heart disease. JAm disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377–3385. Coll Cardiol 2017;69:1363–1371. Corrigendum doi:10.1093/ehjcvp/pvx021 Online publish-ahead-of-print 4 July 2017 .................................................................................................................................................... Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry [Eur Heart J Cardiovasc Pharmacother (2017) 3 (3): 147-150] The above paper has been retrospectively converted to Open Access and had the following funding section added post-publication online: Open access to this publication was supported by Bayer AG. V The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact email@example.com. Downloaded from https://academic.oup.com/ehjcvp/article-abstract/4/2/118/3924495 by Ed 'DeepDyve' Gillespie user on 16 March 2018
European Heart Journal - Cardiovascular Pharmacotherapy – Oxford University Press
Published: Apr 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera